Twist Bioscience Grants Equity Awards to Expand Workforce and Drive Innovation

Twist Bioscience Expands Workforce with Strategic Equity Awards

Twist Bioscience Corporation, a leader in synthetic biology based in South San Francisco, announces a strategic move to enhance its workforce by granting 147,800 equity awards to 43 newly hired employees. This initiative, compliant with Nasdaq regulations, includes 110,300 restricted stock units (RSUs) and performance stock units (PSUs) designated for Colby Souders, the newly appointed Vice President. The equity awards aim to attract top talent essential for driving innovation and growth within the company, as it continues to expand its capabilities in synthetic biology and genomics.

The restricted stock units awarded to the new employees vest over a 48-month period, with an initial 25% vesting on the first anniversary of their start date, followed by quarterly vesting. This structure not only incentivizes ongoing employment but also aligns employee interests with the long-term success of the company. The performance stock units, on the other hand, are tied to specific performance metrics set by the Compensation Committee, with potential earnings varying from 80% to 150% of the target. This dual approach to compensation reflects Twist's commitment to fostering a motivated and high-performing workforce, essential for navigating the complexities of the synthetic biology landscape.

Twist Bioscience's Inducement Equity Incentive Plan is particularly noteworthy, as it allows for equity awards to be granted to individuals who are joining the company for the first time. This flexibility is crucial in attracting experienced professionals who can contribute significantly to the company's objectives. By investing in its human capital, Twist positions itself to leverage its proprietary DNA synthesis platform, which utilizes silicon chips for producing synthetic DNA, to capitalize on various sectors including healthcare, agriculture, and digital data storage. The company’s ongoing efforts to revolutionize the engineering of biology are further bolstered by this strategic recruitment drive.

In addition to enhancing its workforce, Twist Bioscience continues to innovate within the synthetic biology arena. The company's focus on developing solutions that span multiple industries, such as industrial chemicals and biologics drug discovery, underscores its commitment to advancing the field. With these recent equity awards, Twist is not only attracting talent but also reinforcing its mission to be a leader in the rapidly evolving landscape of synthetic biology.

Through these initiatives, Twist Bioscience demonstrates its dedication to building a robust and innovative team that is well-equipped to tackle the challenges and opportunities in the synthetic biology sector. As the company expands its market presence, these strategic workforce enhancements are poised to play a pivotal role in its future successes.